Sparsentan Patent Expiration
Sparsentan is Used for slowing the progression of primary immunoglobulin A nephropathy (IgAN) in adults at risk of rapid disease progression. It was first introduced by Travere Therapeutics Inc
Sparsentan Patents
Given below is the list of patents protecting Sparsentan, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Filspari | US9993461 | Method for treating disorders associated with glomerular function | Mar 29, 2030 | Travere |
Sparsentan's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List